Literature DB >> 8884778

Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain.

K Funa1, N Yamada, G Brodin, K Pietz, A Ahgren, K Wictorin, O Lindvall, P Odin.   

Abstract

The kinetics of platelet-derived growth factor messenger RNA synthesis in the substantia nigra and in the striatum, before and after unilateral intranigral 6-hydroxydopamine injection, was studied and compared with that after sham operation by a quantitative reverse transcription-polymerase chain reaction. The kinetics of brain-derived neurotrophic factor messenger RNA was studied as a comparison. Furthermore, the expression of platelet-derived growth factor A- and B-chain proteins was analysed by enzyme-linked immunosorbent assay and immunohistochemistry. In the ipsilateral striatum of 6-hydroxydopamine-lesioned rats, the signal density of messenger RNA for both A- and B-chains had already increased at one day and remained at an elevated level during the observation period of four weeks. In the substantia nigra ipsilateral to the lesion, a strongly increased level of B-chain and, to a lesser extent, of A-chain messenger RNA was already detected at 4h, reaching a maximal level at one day. No significant increase was seen either in sham-operated rats or in the contralateral striatum and substantia nigra. Amounts of platelet-derived growth factor proteins were examined separately by enzyme-linked immunosorbent assay in both sides of the substantia nigra, striatum and cortex. Three days after 6-hydroxydopamine lesions the levels of both platelet-derived growth factor A- and B-chains increased in the ipsilateral striatum, substantia nigra, and cortex. An increase in the A-chain was also observed in the contralateral side of the brain. The signal for brain-derived neurotrophic factor messenger RNA increased in the striatum in the lesioned side and, to a lesser extent, in the contralateral side, as well as in the substantia nigra, where a significant difference was observed when compared with the contralateral side. Semiquantitative immunohistochemical analysis on the substantia nigra confirmed the enhanced platelet-derived growth factor expression, revealing that the majority of the platelet-derived growth factor-producing cells were neurons. In summary, we have shown that platelet-derived growth factor messenger RNA as well as its protein are induced after injury to dopaminergic cells. These data indicate an important role of platelet-derived growth factor in the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884778     DOI: 10.1016/0306-4522(96)00152-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  13 in total

1.  Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.

Authors:  D Kirik; C Winkler; A Björklund
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Can Parkinson's disease be cured by stimulating neurogenesis?

Authors:  Thomas Foltynie
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

3.  Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.

Authors:  Gesine Paul; Olof Zachrisson; Andrea Varrone; Per Almqvist; Markus Jerling; Göran Lind; Stig Rehncrona; Bengt Linderoth; Hjalmar Bjartmarz; Lisa L Shafer; Robert Coffey; Mikael Svensson; Katarina Jansson Mercer; Anton Forsberg; Christer Halldin; Per Svenningsson; Håkan Widner; Jonas Frisén; Sven Pålhagen; Anders Haegerstrand
Journal:  J Clin Invest       Date:  2015-02-17       Impact factor: 14.808

4.  Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation.

Authors:  T J Collier; C E Sortwell; B F Daley
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

5.  Neuron-specific ablation of PDGF-B is compatible with normal central nervous system development and astroglial response to injury.

Authors:  Maria Enge; Ulrika Wilhelmsson; Alexandra Abramsson; Josefina Stakeberg; Ralf Kühn; Christer Betsholtz; Milos Pekny
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

Review 6.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

7.  Strain difference in the up-regulation of FGF-2 protein following a neurotoxic lesion of the nigrostriatal pathway.

Authors:  David M Yurek; Anita M Fletcher; Laura E Peters; Wayne A Cass
Journal:  Neurochem Res       Date:  2010-04       Impact factor: 3.996

Review 8.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

9.  Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian's Disease.

Authors:  Ji Yong Lee; Hyun Soo Kim; Sung Hoon Kim; Han-Soo Kim; Byung Pil Cho
Journal:  Tissue Eng Regen Med       Date:  2020-01-22       Impact factor: 4.169

Review 10.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.